Status:
TERMINATED
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18-75 years
Brief Summary
To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India. * Efficacy of the treatment with Aromasin® * Safety of the treatment wit...
Detailed Description
NA The study was prematurely discontinued due to slow enrollment and keeping in mind the observational nature of the study. The decision to terminate had been taken on 16th June 2012 and the LSLV occu...
Eligibility Criteria
Inclusion
- Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be eligible.
Exclusion
- Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included.
- Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00776659
Start Date
December 1 2008
End Date
September 1 2012
Last Update
November 19 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bangalore, Karnataka, India, 560 029
2
Pfizer Investigational Site
Ludhiana, Punjab, India, 141 004
3
Pfizer Investigational Site
Ludhiana, Punjab, India, 141 009
4
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India, 226 001